Trial · NCT02861534
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to the First Occurrence of CV Death | Vericiguat | 12.9 | Parts w/ event per 100 part-yrs at risk | ||
| Time to the First Occurrence of CV Death | Placebo | 13.9 | Parts w/ event per 100 part-yrs at risk | ||
| Time to the First Occurrence of HF Hospitalization | Vericiguat | 25.9 | Parts w/ event per 100 part-yrs at risk | ||
| Time to the First Occurrence of HF Hospitalization | Placebo | 29.1 | Parts w/ event per 100 part-yrs at risk | ||
| Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization | Vericiguat | 33.6 | 41.5 to 46.4 | Parts w/ event per 100 part-yrs at risk | |
| Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization | Placebo | 37.8 | 44.4 to 49.4 | Parts w/ event per 100 part-yrs at risk | |
| Time to Total HF Hospitalizations (Including First and Recurrent Events) | Vericiguat | 38.3 | Parts w/ event per 100 part-yrs | ||
| Time to Total HF Hospitalizations (Including First and Recurrent Events) | Placebo | 42.4 | Parts w/ event per 100 part-yrs | ||
| Time to First Occurrence of Composite Endpoint of All-Cause Mortality or HF Hospitalization | Vericiguat | 35.9 | Parts w/ event per 100 part-yrs at risk | ||
| Time to First Occurrence of Composite Endpoint of All-Cause Mortality or HF Hospitalization | Placebo | 40.1 | Parts w/ event per 100 part-yrs at risk | ||
| Time to All-Cause Mortality | Vericiguat | 16.0 | Parts w/ event per 100 part-yrs at risk | ||
| Time to All-Cause Mortality | Placebo | 16.9 | Parts w/ event per 100 part-yrs at risk | ||
| Number of Participants Who Experienced One or More Adverse Events | Vericiguat | 2027 | Participants | ||
| Number of Participants Who Experienced One or More Adverse Events | Placebo | 2036 | Participants | ||
| Number of Participants Who Discontinued Treatment Due to an Adverse Event | Vericiguat | 167 | Participants | ||
| Number of Participants Who Discontinued Treatment Due to an Adverse Event | Placebo | 158 | Participants | ||
| Percentage of Participants Who Experienced Symptomatic Hypotension | Vericiguat | 9.1 | Percentage of participants | ||
| Percentage of Participants Who Experienced Symptomatic Hypotension | Placebo | 7.9 | Percentage of participants | ||
| Percentage of Participants Who Experienced Syncope | Vericiguat | 4.0 | Percentage of participants | ||
| Percentage of Participants Who Experienced Syncope | Placebo | 3.5 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02861534/results